XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $1.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.8% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
Sector
Healthcare
Industry
Biotechnology
Held By 3 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.